R&D channel feed – Endpoints News

R&D channel feed

Fast biotech: Gilead hands $200M to computational wiz Nimbus as it speeds into PhII NASH trial

9 years ago

Shire prunes Sanfilippo A drug after a failed PhIIb

9 years ago

MicroRNA player MiRagen bags $40M round and a public stock listing in reverse merger

9 years ago

Pfizer dumps a fading pipeline star, giving up on its PCSK9 drug bococizumab

9 years ago

After a series of PI3k pileups, Genentech offloads a PhII-ready rival for firesale price

9 years ago

Manufacturing woes derail a blockbuster contender from Sanofi/Regeneron. Who's next?

9 years ago

On the ropes, Opexa shares blasted by PhIIb multiple sclerosis trial flop

9 years ago

Industry vet Ken Moch jumps to the helm of a small biotech with big dreams for treating Alzheimer’s

9 years ago

Billionaire Bezos, Arch carry a torch for aging R&D, back $116M mega-round for Unity

9 years ago

FDA slaps a partial hold on one of AstraZeneca's crucial durvalumab programs

9 years ago

ProQR shares spike on positive PoC study for lead CF drug

9 years ago

Bruised by a punishing Opdivo failure, Bristol-Myers looks to shake up the business, accelerate R&D

9 years ago

GlaxoSmithKline sounds taps for a once-mighty R&D program

9 years ago

Boehringer flags PhIII success for another Humira knockoff, setting up a crowded field of cheaper rivals — eventually

9 years ago

Biogen quietly whisks away its $544M autoimmune rival to Celgene

9 years ago

Merck and Novartis chiefs outline what's on the M&A menu in 2017

9 years ago

AstraZeneca celebrates a PhIII PARP success for Lynparza, putting pressure on Tesaro rival

9 years ago

Portola caps a problem-plagued year with an application for anticoagulant betrixaban

9 years ago

Dipexium shares eviscerated after lead antibiotic flops on a full slate of PhIII endpoints

9 years ago

Novartis promises a speedy CAR-T pitch, boasts about its slate of blockbusters-to-be

9 years ago

Backlash: Harvard experts fret over the fallout from FDA’s OK for Sarepta’s controversial Duchenne drug

9 years ago

Inovio shares slide after FDA hits it with a hold on lead PhIII HPV program

9 years ago

New Listeria fears spotlighted as Aduro’s CRS-207 is slapped with partial hold

9 years ago

Shire bids CTI and its troubled myelofibrosis drug adieu, buying its way out of a deal

9 years ago

First page Previous page 314 315 316317318 319 320 Next page Last page